Research progress of the osteocyte-related biomarkers in predicting osteoporosis and fragility fractures
LI Shiwei1 WANG Boling2 SHI Cheng2 SUN Zhongyang3
1.Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University Nanjing First Hospital, Jiangsu Province, Nanjing 210019, China; 2.Department of Clinical Laboratory, Nanjing Yuhua Hospital Yuhua Branch of Nanjing First Hospital, Jiangsu Province, Nanjing 210039, China;
3.Department of Orthopaedics, the Fifth Clinical College of Anhui Medical University the Air Force Hospital of the Eastern Theater Command, Jiangsu Province, Nanjing 210002, China
Abstract：The traditional bone turnover markers derived from osteoblasts and osteoclasts are useful in the diagnosis and treatment of osteoporosis. However, the usefulness of bone turnover markers in predicting osteoporosis and fragility fractures remains elusive. As the most abundant cell in bone tissue, osteocytes play a central role in regulating bone turnover. Recent research shows that bone turnover markers secreted by osteocytes, such as sclerostin, DKK1, and fibroblast growth factor 23 could be a new type of bone turnover markers for osteoporosis and fragility fracture prediction. This paper will briefly summarize the new research progress of the osteocyte related biomarkers with clinical application prospects in the prediction of osteoporosis and fragility fracture, in order to provide theoretical basis for the diagnosis and evaluation of osteoporosis and fragility fractures.
李仕伟1 王柏灵2 石成2 孙中洋3. 骨细胞相关标志物在骨质疏松症和脆性骨折预测中的研究进展[J]. 中国医药导报, 2023, 20(20): 52-55.
LI Shiwei1 WANG Boling2 SHI Cheng2 SUN Zhongyang3. Research progress of the osteocyte-related biomarkers in predicting osteoporosis and fragility fractures. 中国医药导报, 2023, 20(20): 52-55.
[1] Rubin MR，de Boer IH，Backlund JC，et al. Biochemical mar- kers of bone turnover in older adults with type 1 diabetes [J]. J Clin Endocrinol Metab，2022，107（6）：e2405-e2416.
[2] Brown JP，Don-Wauchope A，Douville P，et al. Current use of bone turnover markers in the management of osteoporosis [J]. Clin Biochem，2022，109/110：1-10.
[3] Slaven SE，Dey D，Yow BG，et al. Longitudinal analysis of circulating markers of bone turnover across multiple decades in osteoporotic women [J]. J Hand Surg Am，2022，47（1）：85.e1-85.e10.
[4] Mohamed Y，Haifa H，Datel O，et al. The role of biochemical markers of bone turnover in the diagnosis of osteoporosis and predicting fracture risk [J]. Tunis Med，2014，92（5）：304-310.
[5] Rupp T，Butscheidt S，Vettorazzi E，et al. High FGF23 levels are associated with impaired trabecular bone microarchitecture in patients with osteoporosis [J]. Osteoporos Int，2019， 30（8）：1655-1662.
[6] Crandall CJ，Vasan S，LaCroix A，et al. Bone turnover markers are not associated with hip fracture risk：a case-control study in the women's health initiative [J]. J Bone Miner Res，2018，33（7）：1199-1208.
[7] Marques EA，Gudnason V，Lang T，et al. Association of bone turnover markers with volumetric bone loss，periosteal apposition，and fracture risk in older men and women：the AGES- Reykjavik longitudinal study [J]. Osteoporos Int，2016，27（12）：3485-3494.
[8] Sarkar S，Reginster JY，Crans GG，et al. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk [J]. J Bone Miner Res，2004， 19（3）：394-401.
[9] Delgado-Calle J，Bellido T. The osteocyte as a signaling cell [J]. Physiol Rev，2022，102（1）：379-410.
[10] Ding P，Gao C，Gao Y，et al. Osteocytes regulate senescence of bone and bone marrow [J]. Elife，2022，11：e81480.
[11] Cui J，Shibata Y，Zhu T，et al. Osteocytes in bone aging：ad- vances，challenges，and future perspectives [J]. Ageing Res Rev，2022，77：101608.
[12] Kim JM，Yang YS，Xie J，et al. Regulation of sclerostin by the SIRT1 stabilization pathway in osteocytes [J]. Cell Death Differ，2022，29（8）：1625-1638.
[13] Michigami T. Roles of osteocytes in phosphate metabolism [J]. Front Endocrinol（Lausanne），2022，13：967774.
[14] Omran A，Atanasova D，Landgren F，et al. Sclerostin：from molecule to clinical biomarker [J]. Int J Mol Sci，2022，23（9）： 4751.
[15] Vasiliadis ES，Evangelopoulos DS，Kaspiris A，et al. The role of sclerostin in bone diseases [J]. J Clin Med，2022，11（3）： 806.
[16] Florio M，Gunasekaran K，Stolina M，et al. A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair [J]. Nat Commun，2016，7：11505.
[17] Recker RR，Benson CT，Matsumoto T，et al. A randomized，double-blind phase 2 clinical trial of blosozumab，a sclerostin antibody，in postmenopausal women with low bone mineral density [J]. J Bone Miner Res，2015，30（2）：216-224.
[18] Coulson J，Bagley L，Barnouin Y，et al. Circulating levels of dickkopf-1，osteoprotegerin and sclerostin are higher in old compared with young men and women and positively associated with whole-body bone mineral density in older adults [J]. Osteoporos Int，2017，28（9）：2683-2689.
[19] Sheng Z，Tong D，Ou Y，et al. Serum sclerostin levels were positively correlated with fat mass and bone mineral density in central south Chinese postmenopausal women [J]. Clin Endocrinol（Oxf），2012，76（6）：797-801.
[20] Zhang H，He JW，Wang C，et al. Associations of polymorphisms in the SOST gene and bone mineral density in postmenopausal Chinese women [J]. Osteoporos Int，2014，25（12）：2797-2803.
[21] Lim Y，Kim CH，Lee SY，et al. Decreased plasma levels of sclerostin but not dickkopf-1 are associated with an increased prevalence of osteoporotic fracture and lower bone mineral density in postmenopausal Korean women [J]. Calcif Tissue Int，2016，99（4）：350-359.
[22] Kaya S，Schurman CA，Dole NS，et al. Prioritization of genes relevant to bone fragility through the unbiased integration of aging mouse bone transcriptomics and human GWAS analyses [J]. J Bone Miner Res，2022，37（4）：804-817.
[23] Li J，Ren Y，Li S，et al. Relationship between sclerostin （SOST） expression and genetic loci rs851056，rs1230399 polymorphisms and bone mineral density in postmenopausal women with type 2 diabetes in Xinjiang [J]. Diabetes Metab Syndr Obes，2021，14：4443-4450.
[24] Szulc P，Boutroy S，Vilayphiou N，et al. Correlates of bone microarchitectural parameters and serum sclerostin levels in men：the STRAMBO study [J]. J Bone Miner Res，2013，28（8）：1760-1770.
[25] Kalem MN，Kalem Z，Akgun N，et al. The relationship between postmenopausal women’s sclerostin levels and their bone density，age，body mass index，hormonal status，and smoking and consumption of coffee and dairy products [J]. Arch Gynecol Obstet，2017，295（3）：785-793.
[26] Tian J，Xu XJ，Shen L，et al. Association of serum Dkk-1 levels with β-catenin in patients with postmenopausal osteoporosis [J]. J Huazhong Univ Sci Technolog Med Sci，2015， 35（2）：212-218.
[27] Suarjana IN，Isbagio H，Soewondo P，et al. The role of serum expression levels of microrna-21 on bone mineral density in hypostrogenic postmenopausal women with osteoporosis：study on level of RANKL，OPG，TGFβ-1，sclerostin，RANKL/OPG Ratio，and physical activity [J]. Acta Med Indones，2019，51（3）：245-252.
[28] Ardawi MS，Rouzi AA，Al-Sibiani SA，et al. High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women：the center of excellence for osteoporosis research study [J]. J Bone Miner Res，2012，27（12）：2592-2602.
[29] Garnero P，Sornay-Rendu E，Munoz F，et al. Association of serum sclerostin with bone mineral density，bone turnover，steroid and parathyroid hormones，and fracture risk in postmenopausal women：the OFELY study [J]. Osteoporos Int，2013，24（2）：489-494.
[30] Kikuchi A，Matsumoto S，Sada R. Dickkopf signaling，beyond Wnt-mediated biology [J]. Semin Cell Dev Biol，2022， 125：55-65.
[31] Park MH，Shin JH，Bothwell ALM，et al. Dickkopf proteins in pathological inflammatory diseases [J]. J Leukoc Biol，2022，111（4）：893-901.
[32] Jiang H，Zhang Z，Yu Y，et al. Drug discovery of DKK1 inhibitors [J]. Front Pharmacol，2022，13：847387.
[33] Butler JS，Murray DW，Hurson CJ，et al. The role of Dkk1 in bone mass regulation：correlating serum Dkk1 expression with bone mineral density [J]. J Orthop Res，2011，29（3）：414-418.
[34] Dovjak P，Dorfer S，F?觟ger-Samwald U，et al. Serum levels of sclerostin and dickkopf-1：effects of age，gender and fracture status [J]. Gerontology，2014，60（6）：493-501.
[35] 程虹，李颖霞，王小琴，等.慢性肾脏病3～5期患者病情程度与α-Klotho、FGF23及钙、磷相关性研究[J].中国医药导报，2020，17（22）：78-81.
[36] Razzaque MS. Interactions between FGF23 and vitamin D [J]. Endocr Connect，2022，11（10）：e220239.
[37] Yamazaki M，Michigami T. Osteocytes and the pathogenesis of hypophosphatemic rickets [J]. Front Endocrinol（Lausanne），2022，13：1005189.
[38] Isakova T，Cai X，Lee J，et al. Associations of FGF23 with change in bone mineral density and fracture risk in older individuals [J]. J Bone Miner Res，2016，31（4）：742-748.
[39] Marsell R，Mirza MA，Mallmin H，et al. Relation between fibroblast growth factor-23，body weight and bone mineral density in elderly men [J]. Osteoporos Int，2009，20（7）：1167-1173.
[40] Imel EA，Liu Z，McQueen AK，et al. Serum fibroblast growth factor 23，serum iron and bone mineral density in premeno- pausal women [J]. Bone，2016，86：98-105.
[41] Han W，Bai XJ，Han LL，et al. The relationship between serum fibroblast growth factor 23，Klotho，and lumbar spine bone mineral density in northern Chinese postmenopausal women [J]. Menopause，2019，26（5）：546-553.
[42] Celik E，Guzel S，Abali R，et al. The relationship between fibroblast growth factor 23 and osteoporosis in postmen- opausal women [J]. Minerva Med，2013，104（5）：497-504.
[43] Mirza MA，Karlsson MK，Mellstr?觟m D，et al. Serum fibroblast growth factor-23 （FGF-23） and fracture risk in elderly men [J]. J Bone Miner Res，2011，26（4）：857-864.
[44] Kanda E，Yoshida M，Sasaki S. Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients [J]. BMC Nephrol，2012， 13：122.
[45] Lane NE，Parimi N，Corr M，et al. Association of serum fibroblast growth factor 23 （FGF23） and incident fractures in older men：the Osteoporotic Fractures in Men （MrOS） study [J]. J Bone Miner Res，2013，28（11）：2325-2332.
京公网安备 11010502046598号